TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development

Stefan H. E. Kaufmann; Hazel M. Dockrell; Nick Drager; Mei Mei Ho; Helen McShane; Olivier Neyrolles; Tom H. M. Ottenhoff; Brij Patel; Danielle Roordink; François Spertini; Steffen Stenger; Jelle Thole; Frank A. W. Verreck; Ann Williams; Warwick Britton; Jamie Triccas; Claudio Counoupas; Johan Grooten; Demoitie Marie-Ange Demoitie; Marta Romano; Kris Huygen; Hermann Giresse Tima; Francoise Mascart; Peter Andersen; Claus Aagaard; Dennis Christensen; Morten Ruhwald; Thomas Lindenstrom; Pierre Charneau; Christophe Guilhot; Antonio Peixoto; Martine Gilleron; Isabelle Vergne; Camille Locht; Roland Brosch; Genevieve Inchauspe; Stephane Leung Theung Long; January Weiner; Jeroen Maertzdorf; Natalie Nieuwenhuizen; Max Bastian; Stephanie Kallert; Stephen Gordon; Nadia Caccamo; Delia Goletti; Roberto Nisini; Sung Jae Shin; Sang Nae Cho; Hyejon Lee; Yvonne Perrie; TBVAC2020 Consortium

doi:10.3389/fimmu.2017.01203

TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development

Stefan H. E. Kaufmann, Hazel M. Dockrell, Nick Drager, Mei Mei Ho, Helen McShane, Olivier Neyrolles, Tom H. M. Ottenhoff, Brij Patel, Danielle Roordink, François Spertini, Steffen Stenger, Jelle Thole, Frank A. W. Verreck, Ann Williams, Warwick Britton, Jamie Triccas, Claudio Counoupas, Johan Grooten, Demoitie Marie-Ange Demoitie, Marta RomanoKris Huygen, Hermann Giresse Tima, Francoise Mascart, Peter Andersen, Claus Aagaard, Dennis Christensen, Morten Ruhwald, Thomas Lindenstrom, Pierre Charneau, Christophe Guilhot, Antonio Peixoto, Martine Gilleron, Isabelle Vergne, Camille Locht, Roland Brosch, Genevieve Inchauspe, Stephane Leung Theung Long, January Weiner, Jeroen Maertzdorf, Natalie Nieuwenhuizen, Max Bastian, Stephanie Kallert, Stephen Gordon, Nadia Caccamo, Delia Goletti, Roberto Nisini, Sung Jae Shin, Sang Nae Cho, Hyejon Lee, Yvonne Perrie, TBVAC2020 Consortium

University Of Strathclyde

Research output: Contribution to journal › Review article › peer-review

41 Citations (Scopus)

94 Downloads (Pure)

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Original language	English
Article number	1203
Pages (from-to)	1-18
Number of pages	18
Journal	Frontiers in Immunology
Volume	8
Issue number	OCT
DOIs	https://doi.org/10.3389/fimmu.2017.01203
Publication status	Published - 4 Oct 2017

Keywords

Bacille Calmette-Guérin
biomarker
clinical trial
discovery
portfolio management
tuberculosis
vaccination

Access to Document

10.3389/fimmu.2017.01203Licence: CC BY 4.0

Kaufmann-etal-FI2017-TBVAC2020-advancing-tuberculosis-vaccines-from-discoveryFinal published version, 1.21 MB

Cite this

Kaufmann, S. H. E., Dockrell, H. M., Drager, N., Ho, M. M., McShane, H., Neyrolles, O., Ottenhoff, T. H. M., Patel, B., Roordink, D., Spertini, F., Stenger, S., Thole, J., Verreck, F. A. W., Williams, A., Britton, W., Triccas, J., Counoupas, C., Grooten, J., Marie-Ange Demoitie, D., ... TBVAC2020 Consortium (2017). TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development. Frontiers in Immunology, 8(OCT), 1-18. Article 1203. https://doi.org/10.3389/fimmu.2017.01203

@article{e6182d725bd548f09a5dd3b85a626b47,

title = "TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development",

abstract = "TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.",

keywords = "Bacille Calmette-Gu{\'e}rin, biomarker, clinical trial, discovery, portfolio management, tuberculosis, vaccination",

author = "Kaufmann, {Stefan H. E.} and Dockrell, {Hazel M.} and Nick Drager and Ho, {Mei Mei} and Helen McShane and Olivier Neyrolles and Ottenhoff, {Tom H. M.} and Brij Patel and Danielle Roordink and Fran{\c c}ois Spertini and Steffen Stenger and Jelle Thole and Verreck, {Frank A. W.} and Ann Williams and Warwick Britton and Jamie Triccas and Claudio Counoupas and Johan Grooten and {Marie-Ange Demoitie}, Demoitie and Marta Romano and Kris Huygen and Tima, {Hermann Giresse} and Francoise Mascart and Peter Andersen and Claus Aagaard and Dennis Christensen and Morten Ruhwald and Thomas Lindenstrom and Pierre Charneau and Christophe Guilhot and Antonio Peixoto and Martine Gilleron and Isabelle Vergne and Camille Locht and Roland Brosch and Genevieve Inchauspe and {Theung Long}, {Stephane Leung} and January Weiner and Jeroen Maertzdorf and Natalie Nieuwenhuizen and Max Bastian and Stephanie Kallert and Stephen Gordon and Nadia Caccamo and Delia Goletti and Roberto Nisini and Shin, {Sung Jae} and Cho, {Sang Nae} and Hyejon Lee and Yvonne Perrie and {TBVAC2020 Consortium}",

year = "2017",

month = oct,

day = "4",

doi = "10.3389/fimmu.2017.01203",

language = "English",

volume = "8",

pages = "1--18",

journal = "Frontiers in Immunology",

issn = "1664-3224",

number = "OCT",

}

Kaufmann, SHE, Dockrell, HM, Drager, N, Ho, MM, McShane, H, Neyrolles, O, Ottenhoff, THM, Patel, B, Roordink, D, Spertini, F, Stenger, S, Thole, J, Verreck, FAW, Williams, A, Britton, W, Triccas, J, Counoupas, C, Grooten, J, Marie-Ange Demoitie, D, Romano, M, Huygen, K, Tima, HG, Mascart, F, Andersen, P, Aagaard, C, Christensen, D, Ruhwald, M, Lindenstrom, T, Charneau, P, Guilhot, C, Peixoto, A, Gilleron, M, Vergne, I, Locht, C, Brosch, R, Inchauspe, G, Theung Long, SL, Weiner, J, Maertzdorf, J, Nieuwenhuizen, N, Bastian, M, Kallert, S, Gordon, S, Caccamo, N, Goletti, D, Nisini, R, Shin, SJ, Cho, SN, Lee, H, Perrie, Y & TBVAC2020 Consortium 2017, 'TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development', Frontiers in Immunology, vol. 8, no. OCT, 1203, pp. 1-18. https://doi.org/10.3389/fimmu.2017.01203

TY - JOUR

T1 - TBVAC2020

T2 - advancing tuberculosis vaccines from discovery to clinical development

AU - Kaufmann, Stefan H. E.

AU - Dockrell, Hazel M.

AU - Drager, Nick

AU - Ho, Mei Mei

AU - McShane, Helen

AU - Neyrolles, Olivier

AU - Ottenhoff, Tom H. M.

AU - Patel, Brij

AU - Roordink, Danielle

AU - Spertini, François

AU - Stenger, Steffen

AU - Thole, Jelle

AU - Verreck, Frank A. W.

AU - Williams, Ann

AU - Britton, Warwick

AU - Triccas, Jamie

AU - Counoupas, Claudio

AU - Grooten, Johan

AU - Marie-Ange Demoitie, Demoitie

AU - Romano, Marta

AU - Huygen, Kris

AU - Tima, Hermann Giresse

AU - Mascart, Francoise

AU - Andersen, Peter

AU - Aagaard, Claus

AU - Christensen, Dennis

AU - Ruhwald, Morten

AU - Lindenstrom, Thomas

AU - Charneau, Pierre

AU - Guilhot, Christophe

AU - Peixoto, Antonio

AU - Gilleron, Martine

AU - Vergne, Isabelle

AU - Locht, Camille

AU - Brosch, Roland

AU - Inchauspe, Genevieve

AU - Theung Long, Stephane Leung

AU - Weiner, January

AU - Maertzdorf, Jeroen

AU - Nieuwenhuizen, Natalie

AU - Bastian, Max

AU - Kallert, Stephanie

AU - Gordon, Stephen

AU - Caccamo, Nadia

AU - Goletti, Delia

AU - Nisini, Roberto

AU - Shin, Sung Jae

AU - Cho, Sang Nae

AU - Lee, Hyejon

AU - Perrie, Yvonne

AU - TBVAC2020 Consortium

PY - 2017/10/4

Y1 - 2017/10/4

N2 - TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

AB - TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

KW - Bacille Calmette-Guérin

KW - biomarker

KW - clinical trial

KW - discovery

KW - portfolio management

KW - tuberculosis

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85030571215&partnerID=8YFLogxK

UR - https://www.frontiersin.org/journals/immunology

U2 - 10.3389/fimmu.2017.01203

DO - 10.3389/fimmu.2017.01203

M3 - Review article

AN - SCOPUS:85030571215

SN - 1664-3224

VL - 8

SP - 1

EP - 18

JO - Frontiers in Immunology

JF - Frontiers in Immunology

IS - OCT

M1 - 1203

ER -

TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (H2020 SC1 PHC)

Cite this

TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Projects

TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (H2020 SC1 PHC)

Cite this